SGN-35
Showing 1 - 25 of 2,941
HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,
Active, not recruiting
- HIV Infection
- +3 more
- brentuximab vedotin
- +3 more
-
Clamart, France
- +5 more
Aug 11, 2022
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)
Completed
- Hodgkin Lymphoma
- Mocetinostat Plus Brentuximab Vedotin
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 10, 2022
Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)
Recruiting
- Recurrent Classic Hodgkin Lymphoma
- Brentuximab Vedotin
- Nivolumab
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 16, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)
Not yet recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Autologous Hematopoietic Stem Cell Transplantation
- +13 more
- (no location specified)
Feb 2, 2023
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell
Recruiting
- Recurrent Angioimmunoblastic T-Cell Lymphoma
- +13 more
- Brentuximab Vedotin
- Pembrolizumab
-
Chicago, IllinoisNorthwestern University
Jun 15, 2022
CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma Trial in Houston (Brentuximab Vedotin, Laboratory Biomarker
Recruiting
- CD30-Positive Neoplastic Cells Present
- Malignant Mesothelioma
- Brentuximab Vedotin
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Jan 3, 2022
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma Trial in Sacramento (Bendamustine Hydrochloride, Brentuximab
Recruiting
- Recurrent Follicular Lymphoma
- Refractory Follicular Lymphoma
- Bendamustine Hydrochloride
- Brentuximab Vedotin
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Dec 17, 2021
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in United
Active, not recruiting
- Ann Arbor Stage IB Hodgkin Lymphoma
- +10 more
- Brentuximab Vedotin
- Nivolumab
-
Palo Alto, California
- +8 more
Jul 20, 2022
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,
Active, not recruiting
- Classic Hodgkin Lymphoma
- +2 more
- Brentuximab Vedotin
- +2 more
-
Duarte, California
- +5 more
Mar 17, 2022
Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab vedotin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 20, 2023
Mycosis Fungoides Trial in Houston (Brentuximab vedotin)
Recruiting
- Mycosis Fungoides
- Brentuximab vedotin
-
Houston, TexasMD Anderson Cancer Center
Oct 14, 2022
AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma Trial in France, United
Active, not recruiting
- AIDS-Related Hodgkin Lymphoma
- +11 more
- Brentuximab Vedotin
- +4 more
-
La Jolla, California
- +27 more
Jul 27, 2022
T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)
Withdrawn
- T Cell Lymphoma
- Brentuximab Vedotin
-
Kansas City, KansasThe University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023
T-Cell Lymphoma Trial (Brentuximab vedotin)
Not yet recruiting
- T-Cell Lymphoma
- Brentuximab vedotin
- (no location specified)
Jun 30, 2022
Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)
Terminated
- Leukemia
- Brentuximab Vedotin
- 5-Azacytidine
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 7, 2022
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large
Recruiting
- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- +3 more
- Brentuximab Vedotin
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Feb 10, 2022
Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)
Not yet recruiting
- Classic Hodgkin Lymphoma
- Biospecimen Collection
- +19 more
- (no location specified)
Jan 6, 2023
Hodgkin Lymphoma, Adult Trial in United States (Brentuximab vedotin, ABVD)
Diffuse Cutaneous Systemic Sclerosis Trial (Brentuximab vedotin)
Not yet recruiting
- Diffuse Cutaneous Systemic Sclerosis
- Brentuximab vedotin
- (no location specified)
Apr 11, 2022
Diffuse Cutaneous Systemic Sclerosis Trial in London (Brentuximab Vedotin)
Recruiting
- Diffuse Cutaneous Systemic Sclerosis
- Brentuximab Vedotin
-
London, Ontario, CanadaRheumatology Clinic, St. Joseph's Health Care
Feb 3, 2022
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular
Recruiting
- Ann Arbor Stage I Hodgkin Lymphoma
- +13 more
- Bleomycin
- +6 more
-
Birmingham, Alabama
- +16 more
Nov 23, 2021
Lymphatic Diseases Trial in Italy (Brentuximab Vedotin)
Completed
- Lymphatic Diseases
- Brentuximab Vedotin
-
Bologna, Italy
- +3 more
Mar 21, 2022